Data from selected patients in the RUBY trial demonstrate improvements in QoL domains over the course of treatment, as well as benefits versus placebo. According

Antitumor responses were comparable to those previously reported for a larger population of advanced melanoma patients. This session was st presented on October 21 at

Some safety and efficacy data of novel immunotherapy agents are encouraging, but additional research is necessary to identify biomarkers and the optimal treatment schedule. This

This late breaking poster was presented on st October 21 at the ESMO Congress at Madrid. Although RAI is commonly used to treat various phases

This late breaking presentation was presented on st October 21 at the ESMO Congress at Madrid. The TGCA data suggest opportunities to target DNA repair

This late breaking presentation was presented on st October 21 at the ESMO Congress at Madrid. Androgen deprivation therapy (ADT) was the standard of care

Adding immunotherapy to the standard of care demonstrates efficacy versus placebo and is confirmed to change clinical practice for this patient population. Pembrolizumab plus standard

The SANO trial also demonstrated clinically complete responses following neoadjuvant chemoradiotherapy. Positive data from the SANO trial presented on th October 20 at the ESMO